Endometriosis Research Center, Iran University of Medical Science, Tehran, Iran.
Pain Research Center, Iran University of Medical Science, Tehran, Iran.
J Obstet Gynaecol. 2021 Aug;41(6):966-971. doi: 10.1080/01443615.2020.1820468. Epub 2020 Nov 26.
We aimed to investigate the effect of superior hypogastric plexus (SHP) block on pain relief and quality of life of patients with refractory endometriosis. Sixteen patients with refractory endometriosis underwent SHP block. The outcome measures included visual analogue scale (VAS) for chronic pelvic pain, VAS for dysmenorrhoea, and VAS for dyspareunia. The short-form endometriosis health profile (EHP-5) was used to measure quality of life. All the outcome measures were evaluated at weeks 0, 1, 4, 12 and 24. The mean baseline VAS scores significantly improved after the SHP block ( < .001 for all). The mean overall EHP-5 score also significantly improved from 54.3 ± 18.2 to 24.6 ± 13.3 ( < .001). The positive effects of SHP were not diminished over time. No serious adverse effect was noticed in any of the patients. Preliminary results suggest that SHP block could be used as an effective method in pain control and improvement of quality of life in refractory endometriosis.IMPACT STATEMENT Safety and efficacy of SHP block in the treatment of CPP has been revealed in earlier investigations. However, the efficacy of SHP block for pain management in patients with refractory endometriosis has not been investigated in earlier investigations. SHP block is an effective method for pain control and improvement of quality of life in patients with refractory endometriosis. The positive effects of this treatment did not diminish over 24-weeks follow-up of the study. No serious adverse effect was noticed in any of the patients. Preliminary results suggest that SHP block could be used safely and effectively for controlling pain and improvement of quality of life in patients with refractory endometriosis.
我们旨在研究腹下神经丛(SHP)阻滞对缓解难治性子宫内膜异位症患者疼痛和提高生活质量的影响。16 例难治性子宫内膜异位症患者接受 SHP 阻滞。观察指标包括慢性盆腔疼痛的视觉模拟评分(VAS)、痛经的 VAS 和性交痛的 VAS。采用简化子宫内膜异位症健康状况量表(EHP-5)评估生活质量。所有观察指标在 0、1、4、12 和 24 周进行评估。SHP 阻滞后,患者的平均基线 VAS 评分显著改善(所有评分均 <.001)。EHP-5 的平均总分也从 54.3 ± 18.2 显著改善至 24.6 ± 13.3(<.001)。SHP 的积极作用随时间推移并未减弱。所有患者均未出现严重不良事件。初步结果表明,SHP 阻滞可能是治疗难治性子宫内膜异位症疼痛和提高生活质量的有效方法。
SHP 阻滞治疗慢性盆腔痛的安全性和疗效在早期研究中已得到证实。然而,早期研究并未探讨 SHP 阻滞治疗难治性子宫内膜异位症患者疼痛管理的疗效。SHP 阻滞是一种治疗难治性子宫内膜异位症患者疼痛和提高生活质量的有效方法。在研究的 24 周随访中,这种治疗的积极作用并未减弱。所有患者均未出现严重不良事件。初步结果表明,SHP 阻滞可安全有效地用于控制难治性子宫内膜异位症患者的疼痛和提高其生活质量。